Phase I/II study of Immunotherapy using Tumor Antigen-pulsed Dendritic Cells in patients with Hepatocellular Carcinoma (HCC)

Clinical response to DC vaccination

Clinical response to DC vaccine

CONTACT US

Summary

This study evaluated the safety, feasibility and efficacy of multiple tumor-associated antigen (TAA)-pulsed DC vaccine in patients with hepatocellular carcinoma. The feasibility, safety and immune activity were confirmed in the patients.

Patients characteristics

5 Patients with hepatocellular stage II and III ages 46-64 years old with previous treatment with Transcatheter hepatic arterial chemoembolization (TACE).

Methodology

• Monocytes were obtained from HCC patients through leukapheresis, PBMCs were separated from WBC by Ficoll-Hypaque density gradient centrifugation.
• PBMCs thawed, washed with Hanks Balanced Salt solution, resuspended in RPMI-1640 medium, supplemented with autologous heat-inactivated plasma and then incubated in culture chambers.
• After 0.5-1 hour incubation at 37C in 5% CO2 incubation, non- adherent cells were removed by gentle washes.
• Adherent cells were cultured with X-VIVO15 supplemented with GM- CSF, IL-4 for 5 days.
• On day 5, non-attached iDC were harvested and pulsed with CTP- fused human AFP, MAGE1 and GPC-3 recombinant proteins at a final concentration of 5 ng/mL each.
• Antigen pulsed DC were matured in the presence of cytokine cocktail, IL-6, IL-1B, TNF-a, prostaglandin E2, IFN-y, OK432 and poly I:C for 1 or 2 days.
• On day 6-7, DC were harvested, washed and resuspended in 1.2mL of cryopreserving solution containing 5% dimethyl sulfoxide.

Treatment

DC vaccine was administered subcutaneously (SC) near inguinal lymph node.

Results

• Toxicity was mild and no grade III/IV serious adverse events.
• No hematological, hepatic or renal toxicity or de novo autoantibody
formation were observed in any of the 5 patients.
• Clinical response achieved in 1 patient with disease stabilization during the follow-up period, however, no tumor response was observed in other 4 patients.
• All 5 patients showed T cell responses against TAAs.

Conclusion

DC vaccine was safe and well tolerated over 6 vaccines in 5 patients. The feasibility, safety and immune activity of DC pulsed with TAAs were confirmed in HCC patients. However clinical response was only detected in 1 patient.

Article Reference link: click here

Scientific article publishing date 9/11/2012

Immucura identifier BSC21_313EN

ALL SCIENTIFIC PAPERS
CONTACT US